India, May 1 -- Qiagen has announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalised form of cancer immunotherapy.

This expanded offering supports standardised, high-precision quality control (QC) workflows and strengthens the position of QIAGEN as a trusted partner for quality control, supporting biotech and biopharma companies, Contract Development and Manufacturing Organisations (CDMO) and therapy developers in CGT manufacturing.

TheQIAcuity RCL Quant Kitdetects replication-competent lentivirus (RCL...